Taking the question as asked, rather than the general version of it. The single most useful discipline is bringing the whole panel to a clinician rather than one flagged value. One out-of-range result in isolation generates anxiety and unnecessary tests; the same result next to the trend and the rest of the panel usually generates a shrug.

I would rather be corrected than agreed with, if it comes to it.

RetaRick_CA said:

The single most useful discipline is bringing the whole panel to a clinician rather than one flagged value.

RetaRick_CA has the substance of this right. The condition it depends on is worth stating. One addition: if the lab changes analytical platform between your draws, the comparison breaks and nobody tells you. It is worth asking when a value moves inexplicably.

I would rather be corrected than agreed with, if it comes to it.

FDA_TrackerJim said:

I got a full panel before starting and a repeat at three months, and the second one is more useful than the first purely because I now have something…

This matches mine closely enough to be worth saying so. Quarterly for the first year is convention rather than evidence, and it is defensible for a simple reason: it is roughly the interval over which HbA1c becomes informative again, since it reflects about three months of glycaemia. After the first year, and once doses are stable, annual is reasonable unless something specific is being followed.

Adding the clinical framing, because it changes how the question reads.

PSA: get baseline labs BEFORE starting baseline bloodwork therapy. You need a "before" picture to measure progress. My recommended pre-treatment panel:

1. CMP + A1C + fasting insulin
2. Complete lipid panel with particle count if possible
3. hsCRP, ferritin, B12, vitamin D
4. Thyroid panel (TSH + free T4)
5. CBC with differential
6. Liver panel (ALT, AST, GGT)
7. DEXA scan or body composition

Total cost at Quest without insurance: ~$200. Worth every penny for the data.